NCT05502367View on ClinicalTrials.gov

A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 10, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Cervical Intraepithelial Neoplasia
Interventions
DRUG

ABI-2280 Vaginal Tablet/Insert

Vaginal Tablet

Trial Locations (7)

2010

RECRUITING

East Sydney Doctors, Darlinghurst

9301

RECRUITING

Farmovs, Bloemfontein

Unknown

RECRUITING

CerviCusco, Cusco

RECRUITING

Ginobs S.A., Lima

RECRUITING

Gole Biomedical Research Centre, Ga-Mothapo

0002

RECRUITING

Nafasi Integrated Solutions, Sunnyside

0184

RECRUITING

Botho ke Bontle Health Services, Waltloo

Sponsors

Lead Sponsor

Antiva Biosciences
All Listed Sponsors
lead

Antiva Biosciences

INDUSTRY

NCT05502367 - A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia | Biotech Hunter | Biotech Hunter